Abstract | OBJECTIVE: METHODS: Two researchers independently used PubMed, ScienceDirect, Cochrane Library, Wanfang Data, CNKI, and VIP databases to search for all relevant studies that met the inclusion criteria and used RevMan 5.3 and STATA 16.0 for data analysis. RESULTS: Fourteen studies that met the inclusion criteria were selected, including 1456 patients. Among the data extracted in this meta-analysis, bone mineral density (BMD) was the primary outcome measurement, while total effective rate, VAS, osteoprotegerin (OPG), bone Gla protein (BGP), bone alkaline phosphatase (BAP), blood P and Ca, and adverse effects were secondary outcome measurements. Our results showed that alendronate combined with atorvastatin is more effective than alendronate alone, with higher BMD, OPG, BGP, and BAP, more significant pain relief, and fewer adverse events. CONCLUSION:
|
Authors | Zhencheng Xiong, Ping Yi, Xiangsheng Tang, Li Shu, Chi Zhang |
Journal | BioMed research international
(Biomed Res Int)
Vol. 2022
Pg. 6747469
( 2022)
ISSN: 2314-6141 [Electronic] United States |
PMID | 35178452
(Publication Type: Journal Article, Meta-Analysis)
|
Copyright | Copyright © 2022 Zhencheng Xiong et al. |
Chemical References |
- Bone Density Conservation Agents
- Osteocalcin
- Atorvastatin
- Alkaline Phosphatase
- Alendronate
|
Topics |
- Alendronate
(pharmacology, therapeutic use)
- Alkaline Phosphatase
- Atorvastatin
(pharmacology, therapeutic use)
- Bone Density
- Bone Density Conservation Agents
(pharmacology)
- Diabetes Mellitus
(drug therapy)
- Female
- Humans
- Osteocalcin
- Osteoporosis
(complications, drug therapy)
- Osteoporosis, Postmenopausal
|